Telix Q2 Revenue Up 21% to $247M

Telix Pharmaceuticals reported US$247 million in Q2 2026 group revenue, up 21% year over year and 7% quarter over quarter, with the Precision Medicine unit delivering US$202 million and leading growth. The company reaffirmed FY2026 guidance to exceed US$1 billion, supported by a US$40 million Regeneron inflow, FDA alignment for TLX591-Tx Phase 3, progress in the BiPASS pre-biopsy program, and ongoing manufacturing expansions and strategic initiatives with Regeneron.